Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Vascular Neurology
•
Invited Professor Series
How can you differentiate perforator disease vs artery-to-artery embolus as a stroke etiology?
Answer from: at Community Practice
The infarct pattern is helpful. Perforator infarcts are deep subcortical infarcts whereas emboli tend to be superficial.
Sign in or Register to read more
16096
Related Questions
Is there benefit of early initiation of antiplatelet therapy or DVT prophylaxis in patients who present with large MCA infarcts and are being considered for hemicraniectomy?
Is there a role for using parenteral anticoagulation for occlusive extensive ICA thrombus with acute onset of symptoms when patients are not candidates for endovascular therapy, such as low NIHSS?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
How does premorbid dementia affect your decision to offer acute stroke intervention?
When might you soften the post-thrombolysis monitoring requirements for patients receiving TPA for acute stroke?
At what point should aspirin therapy for stable cardiovascular disease be discontinued in patients with a diagnosis of chronic cerebral microbleeds or possible Cerebral Amyloid Angiopathy?
What is the value of sending placental pathology in neonatal patients who have suffered an in-utero arterial ischemic stroke?
Do you use dual anti-platelet therapy inpatients with low NIHSS who have had bilateral brainstem strokes?
What factors would influence your decision to use or avoid heparin bridging in patients with mechanical heart valves resuming anticoagulation after intracerebral hemorrhage?
How do you counsel patients who develop DVT or atrial fibrillation requiring anticoagulation when being treated with lecanemab or donanemab?